DD148772A5 - Verfahren zur herstellung n-substituierter aziridin-2-carbonsaeurederivate - Google Patents

Verfahren zur herstellung n-substituierter aziridin-2-carbonsaeurederivate Download PDF

Info

Publication number
DD148772A5
DD148772A5 DD80219137A DD21913780A DD148772A5 DD 148772 A5 DD148772 A5 DD 148772A5 DD 80219137 A DD80219137 A DD 80219137A DD 21913780 A DD21913780 A DD 21913780A DD 148772 A5 DD148772 A5 DD 148772A5
Authority
DD
German Democratic Republic
Prior art keywords
general formula
cyano
group
aziridine
hydrogen
Prior art date
Application number
DD80219137A
Other languages
German (de)
English (en)
Inventor
Elmar Bosies
Wolfgang Kampe
Max Thiel
Uwe Bicker
Dietmar Boerner
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of DD148772A5 publication Critical patent/DD148772A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DD80219137A 1979-02-21 1980-02-19 Verfahren zur herstellung n-substituierter aziridin-2-carbonsaeurederivate DD148772A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792906603 DE2906603A1 (de) 1979-02-21 1979-02-21 N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
DD148772A5 true DD148772A5 (de) 1981-06-10

Family

ID=6063481

Family Applications (1)

Application Number Title Priority Date Filing Date
DD80219137A DD148772A5 (de) 1979-02-21 1980-02-19 Verfahren zur herstellung n-substituierter aziridin-2-carbonsaeurederivate

Country Status (19)

Country Link
US (2) US4397848A (fr)
EP (1) EP0014976B1 (fr)
JP (1) JPS55113760A (fr)
AR (1) AR223863A1 (fr)
AT (1) ATE818T1 (fr)
AU (1) AU529982B2 (fr)
CA (1) CA1148962A (fr)
CS (1) CS208798B2 (fr)
DD (1) DD148772A5 (fr)
DE (2) DE2906603A1 (fr)
ES (1) ES488656A1 (fr)
FI (1) FI70702C (fr)
HU (1) HU182801B (fr)
IE (1) IE49267B1 (fr)
IL (1) IL59425A (fr)
PL (1) PL129707B1 (fr)
PT (1) PT70847A (fr)
SU (1) SU1181541A3 (fr)
ZA (1) ZA80902B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925835A (en) * 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
JPH07301287A (ja) * 1995-03-23 1995-11-14 Sumitomo Heavy Ind Ltd 制御装置に用いられる内接噛合遊星歯車機構
ATE252381T1 (de) * 1997-06-27 2003-11-15 Amplimed Inc Neue cyanoaziridine zur behandlung von krebs
AU2002216672A1 (en) * 2000-11-21 2002-06-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Composition comprising an imexon or derivatives thereof and lipids
US20030129222A1 (en) * 2000-11-21 2003-07-10 Gabriel Lopez-Berestein Liposomal imexon
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL378295A1 (pl) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005121121A2 (fr) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
WO2007035355A2 (fr) * 2005-09-16 2007-03-29 Arena Pharmaceuticals, Inc. Modulateurs du métabolisme et le traitement de troubles s’y rapportant
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2011094008A1 (fr) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta]indol-3-yl) acétique et de ses sels
EP2619198A1 (fr) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
EP4445956A2 (fr) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
WO2016209809A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN113816887A (zh) * 2021-08-31 2021-12-21 华中科技大学 一种氮杂环丙烷类化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2644820A1 (de) * 1976-10-05 1978-04-06 Boehringer Mannheim Gmbh Cancerostatisch und immunstimulierend wirkende 1-(n-acyl-carbamoyl)-2-cyanaziridine sowie verfahren zur herstellung derselben
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen

Also Published As

Publication number Publication date
JPS55113760A (en) 1980-09-02
IE800327L (en) 1980-08-21
FI70702C (fi) 1986-10-06
PL222088A1 (fr) 1980-12-01
ES488656A1 (es) 1980-09-16
CA1148962A (fr) 1983-06-28
AU529982B2 (en) 1983-06-30
SU1181541A3 (ru) 1985-09-23
US4517183A (en) 1985-05-14
US4397848A (en) 1983-08-09
HU182801B (en) 1984-03-28
ZA80902B (en) 1981-03-25
AU5564980A (en) 1980-08-28
EP0014976A1 (fr) 1980-09-03
DE3060268D1 (en) 1982-05-19
PL129707B1 (en) 1984-06-30
EP0014976B1 (fr) 1982-04-07
PT70847A (de) 1980-03-01
IE49267B1 (en) 1985-09-04
FI70702B (fi) 1986-06-26
FI800510A (fi) 1980-08-22
AR223863A1 (es) 1981-09-30
JPH0150700B2 (fr) 1989-10-31
CS208798B2 (en) 1981-09-15
ATE818T1 (de) 1982-04-15
IL59425A (en) 1984-05-31
IL59425A0 (en) 1980-05-30
DE2906603A1 (de) 1980-09-04

Similar Documents

Publication Publication Date Title
DD148772A5 (de) Verfahren zur herstellung n-substituierter aziridin-2-carbonsaeurederivate
DE3005580C2 (fr)
DE2856753A1 (de) N-substituierte omega -aminoalkanoyl- omega -aminoalkansaeuren, ihre verwendung und verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
EP0607775A2 (fr) Utilisation de leflunomid pour inhiber interleukin 1 bêta
EP0104423B1 (fr) Nitro-2-éthènediamines-1,1, procédé pour leur préparation ainsi que leur application comme médicaments
DE2362754C2 (de) Cyclopropylalkylaminoreste enthaltende Oxazolinverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4409236A (en) N-Substituted aziridine-2-carboxylic acid derivatives and immuno-stimulation composition and method
DE69416683T2 (de) Benzolactam-derivate
DE3141387C2 (fr)
DE3027169A1 (de) 3-methylenazetidin-verbindungen und pharmazeutische zubereitungen, welche diese verbindungen enthalten
CH629779A5 (de) Verfahren zur herstellung von benzolsulfonylharnstoffen.
DE2805769C2 (fr)
EP0690066B1 (fr) Dérivés d'acides phosphiniques, leur préparation ainsi que leur utilisation
DE2921844C2 (de) 1-(2-Chlorethyl)-1-nitroso-3-substituierte-3-glycosylharnstoffe, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende pharmazeutische Zubereitungen
CH639067A5 (de) Verfahren zur herstellung von zimtsaeureamiden.
DE2760097C2 (fr)
DE3425452A1 (de) Phenylethylaminopropiophenon-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
AT386195B (de) Verfahren zur herstellung von neuen n-substituierten aziridin-2-carbonsaeurederivaten und ihren salzen
AT366670B (de) Verfahren zur herstellung von neuen acylaminoalkylbenzolsulfonylharnstoffen und von deren salzen
DE3907512C2 (de) Neue Aryloxy-alkylamine, deren Herstellung und diese enthaltende Arzneimittel
DE2354999C3 (de) Dibenzo(b,f)azepin-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AT359082B (de) Verfahren zur herstellung von neuen (1,2-dihydro-2-oxo-nicotinamido)-alkylbenzol- sulfonylharnstoffen und von deren salzen
AT366669B (de) Verfahren zur herstellung von neuen acylaminoalkylbenzolsulfonylharnstoffen und von deren salzen
DE2843008A1 (de) 5(6)-eckige klammer auf (cyclopropylethyl)-sulphinyl eckige klammer zu -benzimidazol-2-methylcarbamat, ein verfahren zu seiner herstellung, sowie pharmazeutische zusammensetzung
DE2365378C2 (fr)

Legal Events

Date Code Title Description
PJ Ceased due to non-payment of renewal fee (addendum to changes before extension act)